Cambridge, MA 02142 For more information call 1-800-828-2088 VYVANSE, the VYVANSE Logo, and ADDERALL XR are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc
The finding that individuals with more pronounced external eating tendencies benefited more from this treatment suggests that its potential to alter unhealthy eating patterns before adverse health conditions develop warrants further exploration
2, 2025 Cell Reports Medicine, The expanding benefits of GLP-1 medicines, July 15, 2025 Endocrine Practice, Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes, Nov
Yolanda Lawson, for a conversation about GLP-1s, blood pressure, menopause, and womens cardiovascular risk